AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 84 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $188,000 | +34.3% | 20,781 | -1.1% | 0.00% | – |
| Q4 2020 | $140,000 | +28.4% | 21,019 | -2.7% | 0.00% | – |
| Q3 2020 | $109,000 | -37.7% | 21,600 | -0.3% | 0.00% | – |
| Q2 2020 | $175,000 | +48.3% | 21,663 | +45.2% | 0.00% | – |
| Q1 2020 | $118,000 | 0.0% | 14,919 | -4.4% | 0.00% | – |
| Q4 2019 | $118,000 | +81.5% | 15,610 | -0.3% | 0.00% | – |
| Q3 2019 | $65,000 | +44.4% | 15,660 | +0.1% | 0.00% | – |
| Q2 2019 | $45,000 | +87.5% | 15,646 | -7.0% | 0.00% | – |
| Q1 2019 | $24,000 | -45.5% | 16,824 | -2.1% | 0.00% | – |
| Q4 2018 | $44,000 | -42.9% | 17,184 | -2.0% | 0.00% | – |
| Q3 2018 | $77,000 | -18.9% | 17,536 | +13.3% | 0.00% | – |
| Q2 2018 | $95,000 | -5.9% | 15,473 | +11.5% | 0.00% | – |
| Q1 2018 | $101,000 | -12.9% | 13,871 | -2.1% | 0.00% | – |
| Q4 2017 | $116,000 | -24.7% | 14,172 | -3.6% | 0.00% | – |
| Q3 2017 | $154,000 | -7.2% | 14,706 | -2.3% | 0.00% | – |
| Q2 2017 | $166,000 | +7.1% | 15,048 | -6.0% | 0.00% | – |
| Q1 2017 | $155,000 | – | 16,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |